205 related articles for article (PubMed ID: 38039964)
1. ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells.
Bergaggio E; Tai WT; Aroldi A; Mecca C; Landoni E; Nüesch M; Mota I; Metovic J; Molinaro L; Ma L; Alvarado D; Ambrogio C; Voena C; Blasco RB; Li T; Klein D; Irvine DJ; Papotti M; Savoldo B; Dotti G; Chiarle R
Cancer Cell; 2023 Dec; 41(12):2100-2116.e10. PubMed ID: 38039964
[TBL] [Abstract][Full Text] [Related]
2. Targeting of low ALK antigen density neuroblastoma using AND logic-gate engineered CAR-T cells.
Halliwell E; Vitali A; Muller H; Alonso-Ferrero M; Barisa M; Gavriil A; Piapi A; Leboreiro-Babe C; Gileadi T; Yeung J; Pataillot-Meakin T; Fisher J; Tucker L; Donovan L; Chesler L; Chester K; Anderson J
Cytotherapy; 2023 Jan; 25(1):46-58. PubMed ID: 36396552
[TBL] [Abstract][Full Text] [Related]
3. Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase.
Walker AJ; Majzner RG; Zhang L; Wanhainen K; Long AH; Nguyen SM; Lopomo P; Vigny M; Fry TJ; Orentas RJ; Mackall CL
Mol Ther; 2017 Sep; 25(9):2189-2201. PubMed ID: 28676342
[TBL] [Abstract][Full Text] [Related]
4. Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma.
Carpenter EL; Haglund EA; Mace EM; Deng D; Martinez D; Wood AC; Chow AK; Weiser DA; Belcastro LT; Winter C; Bresler SC; Vigny M; Mazot P; Asgharzadeh S; Seeger RC; Zhao H; Guo R; Christensen JG; Orange JS; Pawel BR; Lemmon MA; Mossé YP
Oncogene; 2012 Nov; 31(46):4859-67. PubMed ID: 22266870
[TBL] [Abstract][Full Text] [Related]
5. Targeting anaplastic lymphoma kinase (ALK) gene alterations in neuroblastoma by using alkylating pyrrole-imidazole polyamides.
Ota Y; Yoda H; Inoue T; Watanabe T; Shinozaki Y; Takatori A; Nagase H
PLoS One; 2021; 16(9):e0257718. PubMed ID: 34591871
[TBL] [Abstract][Full Text] [Related]
6. Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma.
Pucci P; Lee LC; Han M; Matthews JD; Jahangiri L; Schlederer M; Manners E; Sorby-Adams A; Kaggie J; Trigg RM; Steel C; Hare L; James ER; Prokoph N; Ducray SP; Merkel O; Rifatbegovic F; Luo J; Taschner-Mandl S; Kenner L; Burke GAA; Turner SD
Nat Commun; 2024 Apr; 15(1):3422. PubMed ID: 38653965
[TBL] [Abstract][Full Text] [Related]
7. Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models.
Tucker ER; Jiménez I; Chen L; Bellini A; Gorrini C; Calton E; Gao Q; Che H; Poon E; Jamin Y; Martins Da Costa B; Barker K; Shrestha S; Hutchinson JC; Dhariwal S; Goodman A; Del Nery E; Gestraud P; Bhalshankar J; Iddir Y; Saberi-Ansari E; Saint-Charles A; Geoerger B; Marques Da Costa ME; Pierre-Eugène C; Janoueix-Lerosey I; Decaudin D; Nemati F; Carcaboso AM; Surdez D; Delattre O; George SL; Chesler L; Tweddle DA; Schleiermacher G
Clin Cancer Res; 2023 Apr; 29(7):1317-1331. PubMed ID: 36602782
[TBL] [Abstract][Full Text] [Related]
8. A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment.
Shen J; Najafi S; Stäble S; Fabian J; Koeneke E; Kolbinger FR; Wrobel JK; Meder B; Distel M; Heimburg T; Sippl W; Jung M; Peterziel H; Kranz D; Boutros M; Westermann F; Witt O; Oehme I
Cell Death Differ; 2018 Dec; 25(12):2053-2070. PubMed ID: 29515255
[TBL] [Abstract][Full Text] [Related]
9. Targeting anaplastic lymphoma kinase in neuroblastoma.
Umapathy G; Mendoza-Garcia P; Hallberg B; Palmer RH
APMIS; 2019 May; 127(5):288-302. PubMed ID: 30803032
[TBL] [Abstract][Full Text] [Related]
10. Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed
Liu T; Merguerian MD; Rowe SP; Pratilas CA; Chen AR; Ladle BH
Cold Spring Harb Mol Case Stud; 2021 Aug; 7(4):. PubMed ID: 34210658
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of MEK pathway enhances the antitumor efficacy of chimeric antigen receptor T cells against neuroblastoma.
Tomida A; Yagyu S; Nakamura K; Kubo H; Yamashima K; Nakazawa Y; Hosoi H; Iehara T
Cancer Sci; 2021 Oct; 112(10):4026-4036. PubMed ID: 34382720
[TBL] [Abstract][Full Text] [Related]
12. Bruton's tyrosine kinase potentiates ALK signaling and serves as a potential therapeutic target of neuroblastoma.
Li T; Deng Y; Shi Y; Tian R; Chen Y; Zou L; Kazi JU; Rönnstrand L; Feng B; Chan SO; Chan WY; Sun J; Zhao H
Oncogene; 2018 Nov; 37(47):6180-6194. PubMed ID: 30013190
[TBL] [Abstract][Full Text] [Related]
13. Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib.
Guan J; Fransson S; Siaw JT; Treis D; Van den Eynden J; Chand D; Umapathy G; Ruuth K; Svenberg P; Wessman S; Shamikh A; Jacobsson H; Gordon L; Stenman J; Svensson PJ; Hansson M; Larsson E; Martinsson T; Palmer RH; Kogner P; Hallberg B
Cold Spring Harb Mol Case Stud; 2018 Aug; 4(4):. PubMed ID: 29907598
[TBL] [Abstract][Full Text] [Related]
14. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.
McDermott U; Iafrate AJ; Gray NS; Shioda T; Classon M; Maheswaran S; Zhou W; Choi HG; Smith SL; Dowell L; Ulkus LE; Kuhlmann G; Greninger P; Christensen JG; Haber DA; Settleman J
Cancer Res; 2008 May; 68(9):3389-95. PubMed ID: 18451166
[TBL] [Abstract][Full Text] [Related]
15. Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathways.
Van den Eynden J; Umapathy G; Ashouri A; Cervantes-Madrid D; Szydzik J; Ruuth K; Koster J; Larsson E; Guan J; Palmer RH; Hallberg B
Sci Signal; 2018 Nov; 11(557):. PubMed ID: 30459281
[TBL] [Abstract][Full Text] [Related]
16. Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma.
Pacenta HL; Macy ME
Drug Des Devel Ther; 2018; 12():3549-3561. PubMed ID: 30425456
[TBL] [Abstract][Full Text] [Related]
17. Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells.
Berlak M; Tucker E; Dorel M; Winkler A; McGearey A; Rodriguez-Fos E; da Costa BM; Barker K; Fyle E; Calton E; Eising S; Ober K; Hughes D; Koutroumanidou E; Carter P; Stankunaite R; Proszek P; Jain N; Rosswog C; Dorado-Garcia H; Molenaar JJ; Hubank M; Barone G; Anderson J; Lang P; Deubzer HE; Künkele A; Fischer M; Eggert A; Kloft C; Henssen AG; Boettcher M; Hertwig F; Blüthgen N; Chesler L; Schulte JH
Mol Cancer; 2022 Jun; 21(1):126. PubMed ID: 35689207
[TBL] [Abstract][Full Text] [Related]
18. Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.
Bresler SC; Wood AC; Haglund EA; Courtright J; Belcastro LT; Plegaria JS; Cole K; Toporovskaya Y; Zhao H; Carpenter EL; Christensen JG; Maris JM; Lemmon MA; Mossé YP
Sci Transl Med; 2011 Nov; 3(108):108ra114. PubMed ID: 22072639
[TBL] [Abstract][Full Text] [Related]
19. ALKemy to enhance chimeric antigen receptor T cell immunotherapy for neuroblastoma.
Ruella M
Cancer Cell; 2023 Dec; 41(12):2016-2018. PubMed ID: 38086334
[TBL] [Abstract][Full Text] [Related]
20. High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model.
Richman SA; Nunez-Cruz S; Moghimi B; Li LZ; Gershenson ZT; Mourelatos Z; Barrett DM; Grupp SA; Milone MC
Cancer Immunol Res; 2018 Jan; 6(1):36-46. PubMed ID: 29180536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
